#ANNX

Market Wire News

@marketwirenews.com

1 month ago

JUST IN: ( NASDAQ: #ANNX ) Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

0 0 0 0

@pouchede99.bsky.social

2 months ago

news.1242.com/article/539957

#annx
#パペットスンスン

0 0 0 0

StockTitan

@stocktitan.net

2 months ago

Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026 Annexon (NASDAQ: ANNX) outlined 2026 priorities and registrational milestones for its targeted immunotherapy platform. Key updates: MAA filed for tanruprubart in Europe with a planned U.S. BLA submission in 2026 supported by the FORWARD study; vonaprument Phase 3 ARCHER II enrollment completed (659 patients) with topline data expected in H2 2026; ANX1502 proof-of-concept readout in cold agglutinin disease expected in 2026. Company states a strong cash position funding operations into late 2027 and plans a GA Investor Day in March 2026.

#ANNX Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026

www.stocktitan.net/news/ANNX/annexon-accele...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants Annexon (Nasdaq: ANNX) priced an underwritten public offering to raise approximately $75.0 million in gross proceeds.The offering includes 25,096,153 shares of common stock at $2.60 per share and 3,750,000 pre-funded warrants at $2.599 each, and is expected to close on November 14, 2025, subject to customary conditions. Underwriters have a 30-day option to buy up to 4,326,922 additional shares.

#ANNX Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

www.stocktitan.net/news/ANNX/annexon-announ...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants Annexon (NASDAQ: ANNX) announced on November 12, 2025 that it has commenced an underwritten public offering of $75.0 million of common stock or pre-funded warrants, with a 30-day underwriter option for up to an additional $11.25 million. The proposed offering is being made from a Form S-3 shelf registration declared effective on April 1, 2024 and is subject to market and other conditions.Goldman Sachs, TD Cowen and Wells Fargo Securities are acting as joint book-running managers. Final offering terms will be disclosed in a prospectus supplement to be filed with the SEC; there is no assurance the offering will be completed or on the proposed size or terms.

#ANNX Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

www.stocktitan.net/news/ANNX/annexon-announ...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

6 months ago

Trade Alerts, Monday September 8, 2025 – Crystal Equity Research

Small-cap stocks with bullish MACD Xs, Mon Sept 8th - #TSSI #SEGG #RFIL #PXLW #NEOV #ICHR #EDIT #DAIO #CSTE #BCIC #ANNX #SFL #CMP #BV - More: crystalequityresearch.com/trade-alerts... - #smallcap

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

6 months ago

Leading Indicators, Monday August 18, 2025 – Crystal Equity Research

Small-cap stocks with declining money flow, Mon Aug 18th - #CYN #ONFO #LASE #FBLA #CMND #SEED #PRME #NEXN #MSPR #LMFA #TZUP #IMTE #EVER #DUO #CMBM #ANNX #UIS #SHCO #RSKD #BYON - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones Annexon (NASDAQ:ANNX) reported Q2 2025 financial results and pipeline updates for its complement-mediated disease therapies. The company ended Q2 with $227 million in cash, supporting operations into Q4 2026. Key highlights include:For tanruprubart (GBS treatment): MAA submission in Europe planned for Q1 2026, with ongoing FDA discussions. About 90% of treated patients showed week 1 improvement, with twice as many achieving normal health vs placebo at week 26.For vonaprument (dry AMD treatment): Completed enrollment of 659 patients in Phase 3 ARCHER II trial, with topline data expected in H2 2026. Selected for EMA's PRIME Product Development pilot.Q2 2025 financials show R&D expenses of $44.2M (vs $25.0M in Q2 2024) and net loss of $49.2M ($0.34 per share) compared to $29.6M ($0.23 per share) in Q2 2024. [ "Strong cash position of $227M supporting operations through Q4 2026", "90% of tanruprubart-treated GBS patients showed week 1 improvement, with 2x more achieving normal health vs placebo", "Accelerated enrollment completion of 659 patients in Phase 3 ARCHER II trial for vonaprument", "Selection for EMA PRIME Product Development Coordinator pilot program", "ANX1502 oral C1s inhibitor exceeded target concentration in fasted patients" ]

#ANNX Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

www.stocktitan.net/news/ANNX/annexon-report...

0 0 0 0

@b-rmtltky.bsky.social

7 months ago

「この時間が終わって欲しくない」。

故に、TMSZさんはMCの発言を無視し続け、勝手に喋ってる風の行動をしていた、んじゃないん？
#ANNX

0 0 0 0

Sakae Ganba！

@ske48ganba.bsky.social

9 months ago

#SKE48 #北川愛乃 #石黒友月 #オールナイトニッポンX #ANNX #ニッポン放送

x.com/ANN_Xross/st...

0 0 0 0

Sakae Ganba！

@ske48ganba.bsky.social

9 months ago

AKB48GまいにちアイドルメンバーANNX出演直前SP｜SHOWROOM(ショールーム)

www.showroom-live.com/r/akb48gmain...

#SKE48 #石黒友月 #北川愛乃 #ANNX

0 0 1 0

Sakae Ganba！

@ske48ganba.bsky.social

9 months ago

SHOWROOM

／
本日6/6（金）21:00〜
AKB48G まいにちアイドル2000日メンバー
ANNX出演直前SHOWROOMが決定🎉
＼

ANNXを直前に控えたメンバーたちが
出演への意気込みなど生配信でお届け✨

出演
#石黒友月（ #SKE48）
#橋本陽菜（ #AKB48）
#市村愛里（ #HKT48）
#北川愛乃（ #SKE48）
視聴はこちら👇
showroom-live.com/r/akb48gmain...
#SHOWROOM #ANNX

x.com/SHOWROOM_jp/...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting First Oral Presentation of the Tanruprubart Real-World Evidence (RWE) Study by International Guillain-Barré Syndrome Outcomes Study (IGOS) Researchers Highlights Benefits over Current Standard of Care in Matched Patient Populations Poster Presentations on New Pivotal Phase 3 Analyses Underscore

#ANNX Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting

www.stocktitan.net/news/ANNX/annexon-showca...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones Annexon (NASDAQ: ANNX) reported Q1 2025 financial results and highlighted progress across its late-stage clinical portfolio. The company's lead program tanruprubart is advancing towards BLA submission for Guillain-Barré Syndrome (GBS), with an FDA meeting scheduled for Q2 2025. The company is launching the open-label FORWARD study to provide North American and European access to tanruprubart.Their second program, ANX007, is progressing in Phase 3 ARCHER II trial for dry AMD with geographic atrophy, with enrollment completion expected in Q3 2025 and topline data in H2 2026. The oral small molecule ANX1502 proof-of-concept trial in cold agglutinin disease is set to complete by mid-2025.Financially, Annexon reported $263.7 million in cash and investments as of March 31, 2025, with runway into H2 2026. Q1 2025 net loss was $54.4 million ($0.37 per share), compared to $25.2 million ($0.21 per share) in Q1 2024.

#ANNX Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

www.stocktitan.net/news/ANNX/annexon-report...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting Annexon (NASDAQ: ANNX) announced upcoming presentations at the 2025 Peripheral Nerve Society Annual Meeting highlighting improved outcomes with tanruprubart (formerly ANX005) for treating Guillain-Barré Syndrome (GBS). The presentations, scheduled for May 17-20, 2025 in Edinburgh, UK, will showcase comparative effectiveness data and new analyses from Phase 3 trials.GBS is a rare autoimmune disease causing rapid weakness and potential paralysis, with no current FDA-approved treatments. Tanruprubart, a first-in-kind monoclonal antibody, targets C1q to block classical complement cascade initiation. The drug aims to halt neuroinflammation and nerve damage during acute GBS phase with a single infusion.The presentations will include real-world evidence comparing tanruprubart to standard treatments, data linking early complement inhibition to long-term outcomes, quality of life improvements, and efficacy across a broad patient spectrum.

#ANNX Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting

www.stocktitan.net/news/ANNX/annexon-announ...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

First-Ever Targeted GBS Treatment: Annexon's Phase 3 Data Could Change Patient Care Breakthrough Phase 3 trial results for ANX005, potentially the first targeted therapy for Guillain-Barré Syndrome, to be unveiled at AAN 2025. Full analysis inside.

#ANNX Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting

www.stocktitan.net/news/ANNX/annexon-highli...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

11 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume gains, Mon Mar 17th - #SNCR #QMCO #NIU #LMNR #GES #SES #SOL #YSG #ANNX #CFB #DNTH #GNPX #HYPR - More: crystalequityresearch.com/SmCpStr/ - #smallcap